IL-15 May Offer Selective Chemoprotection: Animal Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 5
Volume 7
Issue 5

BUFFALO, NY--Animal studies have shown that interleukin-15 (IL-15) effectively protects the host from chemotherapy-induced diarrhea, with maintenance of antitumor activity, said Youcef Rustum, PhD, of Roswell Park Cancer Institute, at the first meeting of the Regional Cancer Center Consortium for Biological Therapy of Cancer, hosted by Roswell Park.

BUFFALO, NY--Animal studies have shown that interleukin-15 (IL-15) effectively protects the host from chemotherapy-induced diarrhea, with maintenance of antitumor activity, said Youcef Rustum, PhD, of Roswell Park Cancer Institute, at the first meeting of the Regional Cancer Center Consortium for Biological Therapy of Cancer, hosted by Roswell Park.

In one trial, rats with advanced colorectal cancer were given either fluorouracil modulated by leucovorin or irinotecan (Camptosar) plus one of two doses of IL-15 as the chemoprotective cytokine.

The data in the rats given irinotecan showed two major effects of IL-15 protection (see table). In group IV, the smaller dose of IL-15 (100 µg/kg for 11 doses) offered complete protection against drug-related lethality. In group III, toxicity and subsequent death were increased in the group receiving the largest amount of IL-15 (eight 400 µg/kg doses).

"Thus, the optimal dose and schedule of IL-15 for protection against irinotecan-induced toxicity in this animal model is 100 µg/kg for 11 doses," he said.

The results for IL-15 protection were similar in the rats given fluorouracil and leucovorin. In addition, in these animals, IL-15 potentiated the antitumor activity of fluorouracil/leucovorin, resulting in an increased therapeutic index.

"In similar studies with IL-2, we observed that IL-2 injected daily into rats for 5 days did not protect from chemo-toxicity. Only the rats who received IL-15 were protected selectively from diarrhea," he said. Future studies should include clinical trials using IL-15 to lessen the severity of chemotherapy in cancer patients, Dr. Rustum concluded.

Recent Videos
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
6 experts are featured in this series.
6 experts are featured in this series.
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Related Content